GO
Loading...

Pharmaceuticals

More

  • New kind of trial aims to speed cancer drug development Wednesday, 16 Apr 2014 | 7:01 PM ET

    *AstraZeneca, Pfizer, UK charity link in multi-drug trial. Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial.

  • Environmental groups slam Pa. smog proposal as lax Wednesday, 16 Apr 2014 | 4:48 PM ET

    The Sierra Club, the American Lung Association and other groups say that proposed emissions limits for coal-fired power plants are too lax. The biggest plants would be allowed to release more than 130,000 tons of smog-causing nitrogen oxides annually— 40 percent more than they do now, according to an analysis by the Sierra Club.

  • Illinois-based Astellas to pay $7.3M settlement Wednesday, 16 Apr 2014 | 3:17 PM ET

    NORTHBROOK, Ill.— The U.S. Justice Department announced Wednesday that an Illinois- based pharmaceutical company will pay $7.3 million to resolve allegations involving the marketing of the drug Mycamine. Northbrook- based Astellas Pharma US Inc. manufactures and sells Mycamine, which is used to treat invasive fungus infections.

  • Astellas to pay $7.3M in drug-marketing settlement Wednesday, 16 Apr 2014 | 2:42 PM ET

    NEW YORK— A unit of Japanese drugmaker Astellas Pharma will pay the U.S. government $7.3 million to resolve claims it illegally marketed its antifungal drug Mycamine for children before that use was approved. Another $3.1 million will go to state Medicaid programs. Medicaid did not cover Mycamine for children because the FDA had not yet approved that use.

  • April 16- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday, but combined sales of its nutritional products, medical devices and generic medicines were slightly below Wall Street expectations.

  • GlaxoSmithKline discloses new bribery inquiries Wednesday, 16 Apr 2014 | 12:25 PM ET

    NEW YORK— British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. On Monday the BBC reported that GlaxoSmithKline PLC is facing a bribery investigation in Poland, where a sales representative allegedly paid doctors to prescribe the company's asthma drug Seretide.

  • Judge blocks Massachusetts ban on painkiller Tuesday, 15 Apr 2014 | 3:06 PM ET

    BOSTON— A federal judge has blocked Massachusetts from banning the powerful new painkiller Zohydro. The judge issued a preliminary injunction Tuesday after pharmaceutical company, Zogenix, argued in a lawsuit that the ban issued by Gov.

  • Report: Prescription drug spending climbs in 2013 Tuesday, 15 Apr 2014 | 12:09 PM ET

    Total U.S. prescription drug spending climbed more than 3 percent last year, propelled in part by fewer patent expirations that would have allowed for cheaper generic alternatives, according to the data firm IMS Health. IMS Health also noted that 36 new treatments entered the market last year, including 10 for cancer.

  • April 15- Johnson& Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. J&J on Tuesday said it earned $4.73 billion, or $1.64 per share, in the first quarter.

  • J&J beats forecasts, helped by new medicines Tuesday, 15 Apr 2014 | 10:06 AM ET

    Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.

  • Americans start spending on health care again Tuesday, 15 Apr 2014 | 7:06 AM ET

    Americans used more health services and spent more on prescription drugs in 2013, reversing a recent trend.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • *Q1 sales 11.496 bln Swiss francs vs 11.887 bln forecast. ZURICH, April 15- Adverse currency moves weighed on first-quarter sales at Roche Holding AG, which fell 1 percent, despite a healthy uptake of its new cancer medicines.

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • Biotechs in the green after last week's carnage Monday, 14 Apr 2014 | 2:58 PM ET

    Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.

  • Report: Glaxo bribed doctors in Poland Monday, 14 Apr 2014 | 9:00 AM ET

    LONDON— The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. The British drug company faces corruption probes in China and Iraq.

  • *Allegations follow corruption accusations in China, Iraq. LONDON/ WARSAW, April 14- GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq.

  • April 10- Rite Aid Corp, the third-largest U.S. drugstore operator, forecast fiscal 2015 sales above analysts' estimates as it benefits from the launch of new generic drugs and enrolls more customers in its loyalty programs.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

Most Popular Video

Thursday, 17 Apr 2014 | 5:00 AM ET

Today is CNBC's 25th anniversary. There have been a lot of great moments in the network's history. Here are just a few.

Thursday, 17 Apr 2014 | 3:15 AM ET

Jonny Forsyth, global drinks analyst at Mintel, says China has been a "cash cow" for drink-makers, but the slowdown is having a big impact on sales.

Thursday, 17 Apr 2014 | 1:35 AM ET

CNBC's Helia Ebrahimi discusses the Co-Operative's troubled story from drug buying allegations against the former chairman, to big financial black holes.